Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies
Cet article passe en revue les travaux récents ayant mis en évidence une variabilité génétique entre des tumeurs solides relevant d'une même classification histologique, puis analyse l'inérêt des différentes plateformes technologiques visant à identifier des anomalies génomiques spécifiques prédisant la réponse à une thérapie ciblée
Increased understanding of inter-tumoral heterogeneity at the genomic level has led to significant advancements in the treatment of solid tumors. Functional genomic alterations conferring sensitivity to targeted therapies can take many forms, and appropriate methods and tools are needed to detect these alterations. This review provides an update on genetic variability among solid tumors of similar histologic classification, using non-small cell lung cancer (NSCLC) and melanoma as examples. We also discuss relevant technological platforms for discovery and diagnosis of clinically actionable variants and highlight the implications of specific genomic alterations for response to targeted therapy.
Clinical Cancer Research , résumé, 2014